T cell and autoantibody profiling for primary immune regulatory disorders

Emily M. Harris, MD*[1], Sarah Chamseddine, MD*[2], Anne Chu, BSc[2,3], Leetah Senkpeil, PhD[2], Matthew

Nikiciuk, BSc[2,3] Aleksandra Bourdine, BSc[2], Logan Magin, BSc,[2] Amer Al-Musa, MD[2], Brian Woods,

MMSc[2], Elif Ozdogan, MD[4], Sarife Saker, MD, MMSc[2], David P. Hoytema van Konijnenburg, MD,

PhD[2], Christina S.K. Yee, MD, PhD[2], Ryan W. Nelson, MD, PhD[2], Pui Lee, MD, PhD[2], Olha Halyabar,

MD[2], Rebecca C. Hale, MD, PhD[2], Megan Day-Lewis, MSN[2], Lauren A. Henderson, MD, MMSc[2], Alan

A. Nguyen, MD[2], Megan Elkins, MHS[2], Toshiro K. Ohsumi, PhD[2], Maria Gutierrez-Arcelus, PhD[2],

Janique M. Peyper, MD, PhD[4], Craig D. Platt, MD, PhD[2], Rachael F. Grace, MD, MMSc[1], Brenna

LaBere, MD[2,5#], Janet Chou, MD[2#]

* These authors have contributed equally and are designated to have co-first authorship.

[#] These authors have contributed equally and are designated to have co-last authorship.

Affiliations

[1]Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston,

MA, USA

[2]Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

[3]Northeastern University, Boston, MA

[4]Sengenics, Kuala Lumpur, Malaysia

[5]Current affiliation: Division of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, AZ

85016

Corresponding Author: Janet Chou, 1 Blackfan Circle, Karp #10007D, Boston, MA 02115. Tel: 617-

355-6117. Email: Janet.Chou@childrens.harvard.edu.

Contributor Statement:

EMH, SC, BL, and JC conceptualized the study. AC, MN, AB, LM, ME, and BL obtained consent, processed patient samples, performed experiments, and contributed to data collection and analysis. LS, MG-A, TKO, JMP, EMH, SC, and JC verified and analyzed the data and generated figures. EMH, SC, DPH, CDP, RFG, BL, and JC contributed to patient phenotyping. EMH, SC, and JC wrote the initial version of the manuscript. AA-M, BW, EO, SS, DPH, CSKY, RWN, PL, OH, RCH, MD-L, LAH, AAN,CDP, and RFG provided feedback and revised the manuscript. All authors have read and approved the final version.

Data Sharing Statement:

Deidentified data will be provided to qualified investigators upon reasonable request to the corresponding author.

Funding: This work was supported by the National Institutes of Health (T32HL007574 to EMH, T32AI007512 to SC, BL, DHK, and JC, K12HD052896 to DHK, and R01DK130465 to JC), the Immune Deficiency Foundation (BL), the Thrasher Foundation (EMH), and the Perkin Fund (to JC). The Children's Rare Disease Cohort initiative funded the whole exome sequencing of study participants. Sources of funding had no role in the study design or execution, data interpretation, or writing of the manuscript.

Declaration of Interests: EMH, SC, AC, LS, MN, AB, LM, AA-M, BW, EO, SS, CY, RN, PL, OH, RCH, MD-L, AAN, ME, MG-A, CDP, BL, JC have no conflicts of interest to disclose**.** DHK is a consultant for Adivo Associates and Guidepoint Global. LAH received salary support from the Childhood Arthritis and Rheumatology Research Alliance, investigator-initiated research grants from Bristol Myers Squibb, and consulting fees from Sobi, Pfizer, and Adaptive Biotechnologies. TKO was an employee of

BeBiopharma. JP is an employee of Sengenics. RFG receives research funding from Novartis, Sobi, and

Agios and is a consultant for Agios, Sobi, and Sanofi.

Word Count (abstract): 247

Word Count (text): 4,444

Abstract

Background: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD),

which are often diagnoses of exclusion. Increased $CD4^+CXCR5^+PD1^+$ circulating T follicular helper

(cTfh) cell percentages have been identified as a marker of active disease in some, but not all,

autoimmune disorders.

Objective: To develop a diagnostic approach that combines measurements of cellular and serologic

autoimmunity.

Methods: We recruited 71 controls and 101 pediatric patients with PIRD with autoimmunity. Flow

cytometry was used to measure $CD4^+CXCR5^+$ T cells expressing the chemokine receptors CXCR3 and/or

CCR6. IgG and IgA autoantibodies were quantified in 56 patients and 20 controls using a microarray

featuring 1616 full-length, conformationally intact protein antigens. The 97.5^{th} percentile in the controls

serves as the upper limit of normal for percentages of cTfh cells, $CD4^+CXCR5^+$ T cells expressing

CXCR3 and/or CCR6, and autoantibody intensity and number.

Results: We found that 27.7% of patients had increased percentages of $CD4^+CXCR5^+PD1^+$ cTfh cells and

42.5% had increased percentages of $CD4^+CXCR5^+$ cells expressing CXCR3 and/or CCR6. Patients had

significantly more diverse IgG and IgA autoantibodies than controls and 37.5% had increased numbers of

high-titer autoantibodies. Integrating measurements of cTfh cells, $CD4^+CXCR5^+$ T cells with CXCR3

and/or CCR6, and numbers of high-titer autoantibodies had 71.4% sensitivity (95% CI: 0.5852 – 0.8158)

and 85% specificity (95% CI: 0.6396 – 0.9476) for patients with PIRD compared to controls.

Conclusion: By integrating $CD4^+$ T cell phenotyping and total burden of autoantibodies, this approach

provides additional tools for the diagnosis of PIRD lacking clinical diagnostic criteria.

Highlights Box:

• Primary immune regulatory disorders (PIRD) are heterogenous and often diagnoses of

exclusion if no genetic cause is identified. Current diagnostic tools do not combine

cellular and serologic measures of autoimmunity.

• Measuring activated CD4$^+$ T cells expressing the chemokine receptors CXCR3 and/or

CCR6 and the total number of circulating autoantibodies can enhance detection of

autoimmunity in PIRD beyond the capabilities of currently used tools.

• This study identifies new indicators of autoimmunity that can be feasibly implemented

and leveraged for improving the diagnosis of PIRD.

Key Words: autoimmunity, T follicular helper cells, autoantibodies, primary immune regulatory
disorders
96

97 **Abbreviations:**

AIHA   Autoimmune hemolytic anemia

cTfh   Circulating T follicular helper cell

cTfm   Circulating T follicular memory cell

ES   Evans syndrome

ITP   Immune thrombocytopenia

IVIG   Intravenous immunoglobulin

PIRD   Primary immune regulatory disorders

SLE   Systemic lupus erythematosus

Introduction

Introduction

Primary immune regulatory disorders (PIRD) can target any organ, leading to clinical

heterogeneity that hinders diagnosis.[1] Autoimmunity is a key feature of many types of PIRD[1] Many

autoimmune features, such as immune thrombocytopenia (ITP), are diagnoses of exclusion due to limited

diagnostic testing, and thus necessitate a "watch and wait" management approach that can delay effective

treatment.[2] Positivity for disease-associated autoantibodies does not reliably correlate with disease

activity due to the variable recognition of epitopes inherent in a polyclonal response. Many disease-

associated autoantibodies recognize intracellular antigens whose contributions to disease pathogenesis

remain unknown; furthermore, most disorders have no associated autoantibodies.[3–5] Although next-

generation DNA sequencing has identified some monogenic causes of autoimmunity, most patients lack a

genetic diagnosis.[6] Delayed diagnoses contribute to disease progression and morbidity through postponed

or inadequate treatment. The collective impact of autoimmune disorders worldwide has highlighted the

need for expanding diagnostic options for these patients. [7–10]

Mechanistically, autoimmunity arises from self-reactive T and B cells that generate inflammatory

cytokines and autoantibodies. T follicular helper (Tfh) cells are $CD4^+$ T cells with robust capacity for

inducing B cell activation and class-switching.[11] Upon recognizing antigen, T cells upregulate the

chemokine receptor CXCR5.[12] While effector T cells downregulate CXCR5 upon terminal differentiation,

Tfh cell progenitors maintain expression of this chemokine receptor as it enables their migration to the B

cell follicle.[11] Subsequently, sustained interactions between Tfh and B cells upregulate additional proteins

characteristic of Tfh cells in germinal centers: the transcription factor B cell lymphoma 6 protein (Bcl6)

and the immune checkpoint receptor, programmed cell death 1 (PD-1).[11,13] Notably, the periphery

contains $CD4^+CXCR5^+PD1^+$ T cells that lack expression of Bcl6.[14,15] These cells are commonly referred

to as circulating Tfh (cTfh) cells due to features shared with Tfh cells in the germinal center, including T

cell receptor clonotypes and the ability to induce class-switching.[14–17] Based on these T-B cell interactions

underlying the generation of autoreactive cells, we previously showed that percentages of

$CD4^+CXCR5^+PD1^+$ cTfh cells exceeding 12% of $CD4^+$ T cells have high sensitivity and specificity for

identifying rare and common multi-systemic autoimmune disorders, such as activated protein kinase delta

syndrome and SLE.[18] However, increased percentages of cTfh cells are not a universal feature of all PIRD

indicating the need for additional diagnostic approaches.[19] Measurement of cTfh cells also does not

account for effector T cells that can home to tissues, secrete proinflammatory cytokines, and damage

target organs.

Despite the essential contributions of T and B cells to the development of autoimmune disorders,

existing diagnostic tests do not combine measures of cellular and serologic autoimmunity. To address this

gap, we used an approach that incorporates: (1) measurement of cTfh cells, (2) the expression of

chemokine receptors required for the homing of cTfh and effector T cells to secondary lymphoid organs

and end-organ targets, and (3) quantification of total autoantibody burden using a high-throughput protein

microarray as an indicator of serologic autoimmunity. We focused on patients with PIRD because these

diseases have far fewer diagnostic tools and clinical criteria than common autoimmune diseases. We

recruited patients with diverse types of autoimmunity reflecting the reality of clinical practice and focused

on measures of cellular and serologic autoimmunity that could be implemented in a clinical care setting.

Methods

2.1 Study participants

Informed consent was obtained from patients, all of whom were recruited at Boston Children's

Hospital. This study was approved by the Institutional Review Board (IRB-04-09-113R) of Boston

Children's Hospital. The study included a cohort of 101 patients and 74 controls (**Table 1**).

Information regarding medical diagnoses and treatments received was obtained through review of

the electronic medical record. Race and ethnicity were obtained from self-reported data from the medical

record. Controls were recruited from allergy and hematology outpatient clinics where they were evaluated

for common conditions such as resolving iron deficiency and allergies not requiring treatment. The

control cohort included patients without any history of autoimmunity, immune dysfunction, malignancy,

or transplantation. Patients were classified as having a diagnosis of PIRD as defined by the Primary

Immune Deficiency Treatment Consortium[20] and having autoimmunity based on clinical, laboratory, or

genetic causes abstracted from the medical record by the study's clinical hematologists and

immunologists prior to measurement of cTfh cells. Patients and controls with any clinical signs or

symptoms of acute infection were excluded from the study. Disease activity was defined by abnormal

laboratory values or disease-specific symptoms consistent with the respective autoimmune diagnosis. For

patients with autoimmune cytopenias, these included a platelet count of less than 150K cells/μL,

hemoglobin of less than lower limit of normal for age, and neutrophil count of less than 1500 cells/μL.

For patients with interstitial lung disease, this included pulmonary function tests with a forced vital

capacity (FVC), total lung capacity (TLC), or diffusion capacity for carbon monoxide less than 80%

predicted or a decline of at least 10% in FVC or TLC since the last test.[21] For patients with immune

hepatitis, active disease was defined as the presence of transaminitis and/or positive clinical autoantibody

tests (anti-nuclear antigen, anti-smooth muscle actin, anti-liver kidney microsome type 1 and anti-liver

cytosol 1).[22] For patients with thyroiditis, active disease was defined as abnormal levels of thyroid

stimulating hormone and free thyroxine. For patients with inflammatory bowel disease, active disease was

defined as presence of symptoms or positive findings on endoscopy. For neurologic disorders, ongoing

symptoms related to underlying disease as defined by the treating clinician were considered a marker of

active disease. Patients who had received intravenous immunoglobulin (IVIG) within 4 weeks of

enrollment or rituximab within 12 months of enrollment were considered to be on treatment based on

published kinetics of B cell repopulation in patients with autoimmune disorders.[23,24] Although ITP and

autoimmune neutropenia are considered autoantibody-driven cytopenias, the clinically available

antiplatelet and anti-neutrophil autoantibody assays lack sufficient sensitivity and specificity to be used as

singular diagnostic tests and are not part of the consensus criteria for diagnosing these conditions.[25–27]

Clinical autoantibody testing is not routinely performed for these patients with immune cytopenias at our

center, so this data were not available for our cohort.

2.2 Immunophenotyping

To minimize T cell death that can occur during the process of cell isolation,[28] flow cytometric

assessment of T cells was done on 100 µL of whole blood collected in sodium heparin anticoagulant

tubes. Cell surface staining was performed using the following antibodies: CD4 (BioLegend #317420),

PD-1 (BioLegend, #329907), CXCR5 (BioLegend, #356904), CXCR3 (BioLegend, #353716), and CCR6

(BioLegend, #353434). Similar percentages of cTfm subsets were obtained when anti-CD45RA

(BioLegend #304129) was added to exclude naïve T cells. Flow cytometry data were acquired on BD

LSRFortessa and were analyzed using FlowJo™ v10.8 Software (BD Life Sciences). The upper limit of

normal was defined as the $97 \cdot 5^{th}$ percentile of control values for T cell phenotyping, in accordance with

Clinical and Laboratory Standards Institute (CLSI) guidelines.[29,30] Increased percentages of

$CD4^{+}CXCR5^{+}PD\text{-}1^{+}$ cTfh cells were defined using a threshold of 12% as previously published.[18]

2.3 Autoantibody detection

Sengenics KREX technology (i-OME Discovery array in combination with dual color IgG/IgA

detection) was used to profile seroreactivity against 1616 self-antigens with preserved native

conformation using 100μL of plasma per patient.[31,32] Controls for this platform included 20 age-matched

individuals from the above-described control cohort as well as a commercially available pooled normal

plasma (Sigma) from 50 – 70 individuals without clinical evidence of autoimmunity. Plasma was diluted

1:200 for the assay. Autoantibody binding to antigens was measured using an open format microarray

laser scanner (Agilent) at 10 µm resolution, with quantification of intensities using GenePix Pro 7

software (Molecular Devices). Net fluorescence intensities were calculated by subtracting background

signaling intensities, followed by log2 transformation, Loess normalization[33] using the

normalizeCyclicLoess() function[34] from R package limma[35]. Batch-correction was performed using the

ComBat() function[36] from R package sva.[37] Net normalized intensities are reported in supplementary data

1 and 2. To avoid potential confounding from intravenous immunoglobulin (IVIG), we excluded

autoantibodies with significantly increased intensities in patients who received IVIG within 4 weeks of

study enrollment compared to patients who did not receive IVIG.   High titer autoantibodies were those

with a titer exceeding the 97.5[th] percentile in controls based on Clinical and Laboratory Standards

Institute guidelines for establishing the upper limit of normal.[38] Pathway analysis was performed on high

titer of autoantibody targets with Enrichr using the KEGG 2021 database. Pathways with a false discovery

rate (FDR) <0.05 were considered significant.

2.4 Statistical analysis

Unsupervised hierarchical clustering of autoantibody data was performed using Euclidean

distance and the Ward D2 method with the ComplexHeatmap R package.[39,40] For calculating the

sensitivity and specificity of each assay discussed, 95% confidence intervals (CIs) were computed using

the Brown-Wilson method. To assess the statistical significance of the test's accuracy, a Fisher's exact test

was performed to compare proportions, with a two-tailed p-value less than 0.05 considered statistically

significant. Mann-Whitney test was used for comparisons between two groups. Kruskal-Wallis and

Dunn's multiple comparisons tests were used for comparisons of more than two groups. Statistical tests

were performed using Prism v10.0.0 (GraphPad) or R version 4.3.1. Graphs were created with Prism

v10.0.0 and illustrations were created with BioRender.com. To identify clinical variables associated with

cTfm skewing, a logistic regression was performed using R Statistical Software (version 4.3.1.) with the

mctest package.[41] The outcome variable was dichotomized based on percentages of cTfm above the 97.5th

percentile in controls, with participants classified as having skewed or non-skewed percentages. The

clinical variables included in the analysis were: diagnosis of a monogenic disorder, the presence or

absence of immunomodulatory treatment, and presence or absence of disease activity. Statistical

significance was set at $p < 0.05$

Results

Patient characteristics

This study enrolled 175 individuals: 101 patients with PIRD and autoimmunity and 74 controls (**Table 1**). The clinical heterogeneity of this patient cohort reflects the phenotypic variability intrinsic to PIRD[1,42]. Immune cytopenias were the most common clinical feature, affecting 80% of the patients. This included 24 patients with ITP, 22 with autoimmune hemolytic anemia (AIHA), and 35 with Evans syndrome (ES). Additional autoimmune conditions in this cohort included hepatitis, intestinal disease, interstitial lung disease, neurologic disease, and thyroiditis (**Table 1**). There were 28 patients (28%) with a monogenic diagnosis (**Supplementary table 1**). At enrollment, 59 patients (58%) had active disease and 74 (73%) were receiving treatment (**Table 1**). A total of 27 patients had a history of rituximab treatment prior to enrollment, of whom 13 had received it within 12 months before enrollment.

Patients with PIRD have chemokine receptor-skewed cTfm cells

We previously published that percentages of $CD4^+CXCR5^+PD-1^+$ cTfh cells exceeding 12% of $CD4^+$ T cells have 88% sensitivity and 94% specificity for active, multi-systemic autoimmunity and can normalize with immunomodulatory treatment.[18] In this cohort, patients with PIRD had significantly higher cTfh than controls (median 7.9% in patients, 5.2% in controls, p<0.0001). In contrast to our prior study, the majority of this cohort (72.2%, 73 patients) had a normal percentage of $CD4^+CXCR5^+PD-1^+$ cTfh cells **(Fig. 1a)**. These patients had disease features known to be associated with normal cTfh cell percentages:[18] inactive disease (n=35), autoimmunity affecting a single organ without evidence of multi-systemic disease (n=45), and treatment with immunomodulatory therapies (n=42)**.**

We investigated additional features of antigen-activated $CD4^+$ T cells as potential indicators of autoimmunity. We focused on $CD4^+CXCR5^+$ T cells since CXCR5 upregulation occurs after antigen-dependent, cognate interactions essential in autoimmunity.[12] As $CD4^+$ T cells expressing $CXCR5^+$ include Tfh cells, cTfh cells, or memory effector cells,[43] we refer to cells in this early state as circulating T

follicular memory (cTfm) cells. We hypothesized that CXCR3 and CCR6 could serve as additional markers of autoimmunity, as these chemokine receptors are upregulated on both cTfh cells and effector memory T cells by inflammatory cytokines and enable recruitment of T cells to inflamed tissues.[14,44] Prior studies have shown that individuals with a wide range of autoimmune disorders have expansion of cTfh and effector memory T cells expressing different combinations of these chemokine receptors: $CXCR3^+CCR6^-$, $CXCR3^+CCR6^+$, $CXCR3^-CCR6^+$, or $CXCR3^-CCR6^-$.[11,45] Since the proinflammatory cytokines driving CXCR3 and CCR6 fluctuate dynamically during the disease course of autoimmunity, we investigated chemokine receptor skewing of cTfm cells as an indicator of autoimmunity (**Figure 1b**). We defined chemokine-receptor cTfm skewing as percentages of $CXCR3^+$ and/or $CCR6^+$ cTfm exceeding the 97.5[th] percentile of those found in controls (**Figure 1c**), a threshold used in clinical laboratory standards for the upper limit of normal.[38] Among 101 patients with PIRD 43% of patients had skewed cTfm cells. $CXCR3^+CCR6^-$ and $CXCR3^+CCR6^+$ cTfm cells were the most commonly increased populations in patients, leading to reciprocally reduced percentages of $CXCR3^-CCR6^-$ cTfm cells (**Figure 1c**). Of the 73 patients with normal cTfh, 24 (32.9%) had skewed cTfm cells (**Figure 1d**). cTfm skewing did not differ based on disease activity ($p=0.59$), treatment status ($p=0.20$), or diagnosis of monogenic disorder ($p=0.32$) by multivariate regression (**Figure 1e**). Neither cTfh nor cTfm skewing differed by type of immunomodulatory therapy (**Supplementary Figure 1**). Most patients had non-overlapping patterns of cTfm skewing (**Figure 1f**). Prior studies have identified increased percentages of circulating $CD4^+CXCR5^-PD1^{high}$ T peripheral helper (Tph) cells in patients with different types of autoimmune diseases, particularly in common autoimmune disorders, such as rheumatoid arthritis. In our cohort, patients with PIRD had higher percentages of Tph cells compared to controls, with 15 patients having a Tph cell percentage exceeding the 97.5[th] percentile of controls (**Supplementary Figure 2**). Of these 15 patients, 14 had skewed cTfm cells.

Patients with PIRD have a high burden of autoantibodies

To complement measures of T cell activation, we investigated autoantibody profiles in a

representative sub-cohort of 56 patients with PIRD and 20 controls from our total study cohort. We used

an analytic approach that addressed specific challenges hindering the use of autoantibody profiling as a

diagnostic tool. First, very few pathogenic autoantibodies have been identified for autoimmune diseases,

even for those treated with B cell depleting agents.[7] Additionally, pediatric patients with PIRD are

typically too few in number to power studies characterizing autoantibody repertoires for specific diseases.

To circumvent these limitations, we hypothesized that patients with PIRD would have an increased total

number and/or diversity of autoantibodies compared to controls, regardless of disease sub-phenotype or

autoantibody target. To do this, we used a platform that detects IgG and IgA autoantibodies to 1616

conformationally intact, full-length human proteins related to autoimmunity and cancer.[31,32] High-titer

autoantibodies were classified as those with normalized intensities exceeding three standard deviations of

those found in controls. This approach identified a high-titer anti-muscle-specific tyrosine kinase in a

patient with myasthenia gravis in the setting of Kabuki syndrome, concordant with clinical testing for

autoantibodies in this patient. The targets of high-titer IgG and IgA autoantibodies were predominantly

intracellular antigens, likely reflecting antigen release after cell death (**Supplementary Data 3 and 4**).[46]

We defined a high autoantibody burden as a total number of high-titer autoantibodies exceeding the 97.5

percentile of those in controls, which was 15 for IgG and 4 for IgA. Patients had a median of five high-

titer IgG autoantibodies (range: 0 – 249 autoantibodies per patient) compared to a median of 1.5 high-titer

IgG autoantibodies in controls (range: 0 – 16 autoantibodies per control, **Figure 2a**). There were 530

high-titer IgG autoantibodies found only in the patients with PIRD (**Supplementary Data 3**), whose

targets were significantly enriched in pathways pertaining to cell cycling, cell senescence, insulin

signaling, mitophagy, and PI3K/AKT/mTOR, a metabolic pathway important for cTfh and effector T cell

dysregulation as well as autoimmune cytopenias (**Figure 2b**).[47,48] Among the eight patients with high IgG

autoantibody burden, two had received IVIG within the four weeks preceding enrollment. The remaining

15 patients who had received IVIG within the four weeks prior to enrollment had normal IgG

autoantibody burdens. Therefore, patients who received IVIG therapy were not overrepresented among

305 those with a high autoantibody burden. In addition, pathway analysis of high titer- IgG autoantibodies

306 did not differ when IVIG recipients were excluded from the analysis (**Supplementary Data 5**). Among

307 the 32 patients with active disease, six had high IgG autoantibody burden. There were eight patients with

308 active disease who were not on immunomodulatory treatment at the time of enrollment, only one of

309 whom had an elevated IgG autoantibody burden.

311  Patients had a median of two high-titer IgA autoantibodies (range: 0 – 232) and increased

312 autoantibody diversity as compared to a median of one high-titer IgA autoantibody in controls (range: 0 –

313 5, **Figure 2c**). There were 526 high-titer IgA autoantibodies found only in the patients with autoimmunity

314 (**Supplementary Data 4**), whose targets were significantly enriched in pathways pertaining to cellular

315 senescence, mitophagy, ferroptosis, and glucose metabolism (**Figure 2d**). These pathways have been

316 previously shown to contribute to autoimmunity and overlap with those enriched in targets of high-titer

317 IgG autoantibodies.[49,50] There were 17 patients with high IgA autoantibody burden, ten of whom had

318 active disease. Among the eight patients with active disease who were not on immunomodulatory

319 treatment at the time of enrollment, two had an elevated IgA autoantibody burden. In this cross-sectional

320 study, the number of high-titer IgG or IgA autoantibodies was not different in patients with active disease

321 or ongoing treatment (**Supplementary Figure 3**). Autoantibody burden was not significantly associated

322 with cTfh elevation (p=0.7715) or cTfm skewing (p=0.5911, **Figure 3a**).

324  To determine if any specific autoantibodies clustered with clinical phenotypes, we performed

325 unsupervised hierarchical clustering of all autoantibodies in patients and controls. Although we did not

326 find an association between IVIG and the total number of high-titers autoantibodies, IVIG is known to

327 confound analyses of specific autoantibodies in patient populations.[51,52] Therefore, we eliminated patients

328 who received IVIG within four weeks of study enrollment from the unsupervised hierarchical clustering

329 of autoantibodies (**Supplementary Figure 4**). This analysis did not identify any specific autoantibodies

330 associated with clinical phenotypes (**Supplementary Figure 4**). Unsupervised hierarchical clustering of

IgA autoantibodies also did not identify any discernable pattern of autoantibodies associated with clinical

features (**Supplementary Figure 5**). Collectively, these findings show that quantification of the

autoantibody burden may provide an alternative approach for identifying autoimmunity in patients

lacking specific autoantibody targets.

Combining cTfh, cTfm skewing, and autoantibody profiling for the diagnosis of autoimmunity

Based on the dual contributions of T and B cells in the development of autoimmunity, we tested

the sensitivity and specificity of a composite measure integrating increased percentages of cTfh cells and

chemokine receptor-skewed cTfm, and a high burden of high-titer IgG and/or IgA autoantibodies for

autoimmunity within the cohort of 56 patients and 22 controls for whom all measurements were available.

cTfh elevation had sensitivity of 32.1% (95% CI: 0.2410 - 0.4518) and specificity of 100% (95% CI:

0.8389 – 1.0000) for autoimmunity. cTfm skewing had sensitivity of 42.9% (95% CI: 0.3077 – 0.5586)

and specificity of 95.0% (95% CI: 0.7639 – 0.9974) for autoimmunity and identified an additional 11 of

38 of patients who had normal percentages of cTfh cells. High IgG or IgA autoantibody burden had

sensitivity of 37.5% (95% CI: 0.2601 – 0.5059) and specificity of 90.0% (95% CI: 0.6990 – 0.9822) for

autoimmunity and identified an additional 11 of 27 patients who had normal percentages of cTfh and no

cTfm skewing. The composite measure of cTfh elevation, cTfm subset skewing, and increased

autoantibody burden had sensitivity of 71.4% (95% CI: 0.5852 – 0.8158) and specificity of 85.0% (95%

CI: 0.6396 – 0.9476) for autoimmunity in this cohort of patients. (**Figure 3b, c**).

Discussion

Here, we demonstrate new approaches for characterizing patients with PIRD. Prior studies have

identified increased percentages of CD4[+] T cells expressing CXCR3 and/or CCR6 in different diseases,

leading to apparent discrepancies in the subtypes associated with different diseases.[53] As upregulation of

these chemokine receptors is influenced by dynamic changes in inflammatory cytokines inherent in PIRD,

we show that chemokine receptor skewing itself is a feature that can be used to detect autoimmunity. The

quantification of chemokine receptor-skewed CD4[+]CXCR5[+] cells uses equipment and techniques readily

available in most clinical laboratories with a low reagent cost.[54] Although the reagent cost of a diverse

autoantibody array is more substantial[55], this assay uses a commercially available protein microarrays and

an open-format microarray scanner available in clinical laboratories. This approach complements

clinically available measurements of specific antibodies as it can assess serologic autoimmunity even

when known pathogenic autoantibodies are unknown or undetectable.

The diversity of clinical phenotypes, disease activity, and therapies in our patient cohort reflects

the clinical reality of PIRD. For example, the differential diagnosis for isolated thrombocytopenia

includes ITP as well as many other non-autoimmune causes, including familial thrombocytopenia, bone

marrow failure syndromes, medication-induced thrombocytopenia, and platelet sequestration in the liver

or spleen.[25,27,56] ITP remains a diagnosis of exclusion, as there are no laboratory tests for diagnosing ITP

and current clinical tests for anti-platelet glycoprotein autoantibodies have 53% sensitivity for ITP. Even

at centers with a large volume of immune cytopenia cases, up to 14% of children and 12.2% of adults

who were diagnosed with ITP were misdiagnosed, while 3.1% of patients diagnosed with other causes of

thrombocytopenia were ultimately found to have ITP. [25,27,56] Similarly, autoimmune neutropenia is a

diagnostic challenge due to the lack of a diagnostic tests specific for autoimmune neutropenia.[26] Notably,

we were able to detect increased percentages of cTfm skewing even in patients with ongoing

immunomodulatory treatment. Therefore, a composite measure based on cellular and humoral

mechanisms of autoimmunity, rather than disease-specific antigens, may address these diagnostic

challenges.

We previously showed that percentages of circulating $CD4^+CXCR5^+PD1^+$ cTfh cells exceeding

12% of $CD4^+$ T cells have high sensitivity and specificity for active, multi-systemic autoimmunity.[18]

Unlike our current study, the prior patient cohort had autoimmunity affecting more than one organ

system. Our work complements published studies showing increased cTfh levels in patients with specific

autoimmune disorders, such as SLE, rheumatoid arthritis, and Sjogren syndrome.[11,19] Less is known about

the dysregulation of cTfh cells in patients with autoimmune cytopenias, which affected 84% of the

patients in our study. In a cohort of 24 patients with Evans syndrome due to the presence of at least two

types of autoimmune cytopenias and 22 patients with chronic ITP, Kumar et al. found that patients with

Evans Syndrome have increased percentages of cTfh cells and $CXCR3^+CXCR5^+PD-1^+$ T cells compared

to those with chronic ITP.[57] While this prior study focused on the $CD4^+CXCR5^+PD-1^+$ T cells, we

quantified total $CD4^+CXCR5^+$ T cells regardless of PD-1 expression. We chose this approach because

$CD4^+CXCR5^+$ T cells lacking PD-1 can also contribute to autoimmunity by eventually differentiating into

effector memory T cells expressing either CXCR3 or CCR6.[58] Measurement of $CD4^+CXCR5^+$ cTfm cells

thus encompasses different types of antigen-experienced T cell populations with distinct contributions to

autoimmunity. The increased expression of $CXCR3^+$ on cTfm cells in our patient cohort (**Figure 1C**) may

be arising at least in part from the known roles of IFN-γ in upregulating CXCR3 and in driving

autoimmunity.[59–61] We also show that all but one of the patients with increased Tph cells also had

chemokine-skewed cTfm cells. Although these two populations are differentiated by the absence (Tph) or

presence (cTfm) of $CXCR5^+$, the expansion of Tph cells, like upregulation of CXCR3 and CCR6,[14,44] is

driven by inflammatory cytokines.[62] We did not integrate Tph cells with other measures of autoimmunity

because Rao *et al.* have noted that these cells are infrequent in blood and that studies of Tph cells

enriched in inflamed tissue sites, rather than those circulating in the periphery, are the most informative.[63]

We found that percentages of chemokine receptor-skewed cTfm cells did not correlate with

whether patients were receiving ongoing immunomodulatory treatment. The most common treatments

used in this cohort were glucocorticoids and rituximab. This is clinically relevant since empiric

immunosuppressive therapy is sometimes required for management of acute and/or severe autoimmunity

before the diagnostic evaluation is complete. Thus, measurement of chemokine receptor-skewed cTfm

cells may serve as an indicator of autoimmunity even if other inflammatory markers are normalized by

immunomodulatory therapies. Effector T cells expressing CXCR3 and CCR6 have been shown to resist

glucocorticoid-induced cell death due to the expression of the multi-drug resistance type 1 membrane

transporter, which enable excretion of glucocorticoids, and low expression of the glucocorticoid receptor,

further reducing signaling downstream of glucocorticoids.[64,65] We hypothesize that these mechanisms

may underlie the resistance of cTfm cells to treatment, but additional studies are needed to determine this.

We complemented these studies of cTfm subsets with a broad autoantibody profiling to assess the

overall burden of high-titer autoantibodies since disease-associated autoantibodies are unknown for many

autoimmune disorders. Even for disorders with known autoantibodies, the relationship between

autoantibodies and disease activity is unpredictable, since autoantibodies can develop before clinical

manifestations of autoimmune diseases.[2] Our pediatric patient cohort with PIRD harbored a diverse set of

high-titer IgG and IgA autoantibodies not found in controls, with more patients having an increased

number of high-titer IgA than IgG autoantibodies. The high-titer IgA autoantibodies unique to the patients

targeted self-antigens enriched in pathways similar to those targeted by the IgG autoantibodies,

suggesting that screening for IgA autoantibodies may comprise another readout for some patients with

PIRD. Measuring IgA autoantibodies also circumvents potential confounding from IVIG, although we

found no correlation between IVIG treatment and an increased total autoantibody burden. Pathway

analysis for enriched high titer- IgG antibodies was also similar regardless of IVIG status. We did not find

an association between cTfh cells and the numbers of high-titer autoantibodies, consistent with studies

showing that additional factors, including subtypes of B cells and the cytokine milieu, are needed for the

generation of autoantibodies. [2]

This study has several limitations. This study did not include patients with clinical or laboratory

evidence of a concomitant infection since infections affect many features of autoimmune diseases,

including percentages of cTfh cells and effector memory T cells, inflammatory markers, and cytokine

levels.[66–68] Most of the patients in this study had active disease at the time of enrollment, reflecting the

chronic and persistent nature of these disorders. Future longitudinal studies are needed to delineate how

cTfm and autoantibody profiles change through a patient's disease course. Thus, the clinical context is

essential for interpreting these studies. Our study was not powered to identify specific autoantibodies

associated with disease phenotypes. Rather, we identified features that can be used to characterize PIRD,

which are often diseases of exclusion, without known pathogenic autoantibodies or cellular markers of

autoimmunity. Further studies are needed to determine if the measures investigated in this study are

generalizable to cohorts from other countries, genetic backgrounds, older age groups, and more common

autoimmune diseases.

In conclusion, this study applied two consequences of sustained T-B cell crosstalk to identify new

approaches for characterizing diverse types of autoimmunity. We show that chemokine skewing of

$CD4^+CXCR5^+$ cTfm cell subsets and quantification of the total burden of autoantibodies can help identify

autoimmunity even when percentages of cTfh cells are normal. These approaches thus present new

avenues for improved characterization of rare and diverse disorders of autoimmunity.

Acknowledgments: We are grateful to our patients and their families for their participation in this study.

References

1. Gray PE, David C. Inborn Errors of Immunity and Autoimmune Disease. The Journal of Allergy and
Clinical Immunology: In Practice. 2023 Jun;11(6):1602–22.

2. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023 Aug;19(8):509–24.

3. Roth AJ, Ooi JD, Hess JJ, Timmeren MM van, Berg EA, Poulton CE, et al. Epitope specificity
determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013 Apr
1;123(4):1773–83.

4. Sciascia S, Bizzaro N, Meroni PL, Dimitrios B, Borghi MO, Bossuyt X, et al. Autoantibodies testing
in autoimmunity: Diagnostic, prognostic and classification value. Autoimmunity Reviews. 2023
Jul;22(7):103356.

5. Ma H, Murphy C, Loscher CE, O'Kennedy R. Autoantibodies - enemies, and/or potential allies?
Front Immunol. 2022 Oct 19;13:953726.

6. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human
Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of
Immunological Societies Expert Committee. J Clin Immunol [Internet]. 2022 Jun 24 [cited 2022
Aug 20]; Available from: https://link.springer.com/10.1007/s10875-022-01289-3

7. Lenti MV, Rossi CM, Melazzini F, Gastaldi M, Bugatti S, Rotondi M, et al. Seronegative
autoimmune diseases: A challenging diagnosis. Autoimmunity Reviews. 2022 Sep;21(9):103143.

8. Kernder A, Richter JG, Fischer-Betz R, Winkler-Rohlfing B, Brinks R, Aringer M, et al. Delayed
diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of
the LuLa cohort. Lupus. 2021 Mar;30(3):431–8.

9. Solomon AJ, Marrie RA, Viswanathan S, Correale J, Magyari M, Robertson NP, et al. Global
Barriers to the Diagnosis of Multiple Sclerosis. Neurology. 2023 Aug 8;101(6):e624–35.

10. Wylezinski LS, Gray JD, Polk JB, Harmata AJ, Spurlock CF. Illuminating an Invisible Epidemic: A
Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in
Inflammatory Disease and Related Syndromes. Journal of Clinical Medicine. 2019 Apr;8(4):493.

11. Walker LSK. The link between circulating follicular helper T cells and autoimmunity. Nat Rev
Immunol. 2022 Sep;22(9):567–75.

12. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. Cxc Chemokine Receptor 5
Expression Defines Follicular Homing T Cells with B Cell Helper Function. J Exp Med. 2000 Dec
4;192(11):1553–62.

13. Ruterbusch M, Pruner KB, Shehata L, Pepper M. In Vivo CD4 $^+$ T Cell Differentiation and Function:
Revisiting the Th1/Th2 Paradigm. Annu Rev Immunol. 2020 Apr 26;38(1):705–25.

14. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood
CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that
differentially support antibody secretion. Immunity. 2011 Jan 28;34(1):108–21.

15. Ueno H. Human Circulating T Follicular Helper Cell Subsets in Health and Disease. J Clin Immunol.
2016 May;36(S1):34–9.

16. Vella LA, Buggert M, Manne S, Herati RS, Sayin I, Kuri-Cervantes L, et al. T follicular helper cells
in human efferent lymph retain lymphoid characteristics. J Clin Invest. 129(8):3185–200.

17. Brenna E, Davydov AN, Ladell K, McLaren JE, Bonaiuti P, Metsger M, et al. CD4+ T Follicular
Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh
CD4+ Cells. Cell Rep. 2020 Jan 7;30(1):137-152.e5.

18. LaBere B, Nguyen AA, Habiballah SB, Elkins M, Imperial J, Li B, et al. Clinical utility of measuring
CD4+ T follicular cells in patients with immune dysregulation. Journal of Autoimmunity. 2023 Nov
1;140:103088.

19. Gensous N, Charrier M, Duluc D, Contin-Bordes C, Truchetet ME, Lazaro E, et al. T Follicular
Helper Cells in Autoimmune Disorders. Front Immunol. 2018 Jul 17;9:1637.

20. Primary Immune Deficiency Treatment Consortium [Internet]. [cited 2025 Jan 22]. Available from:
https://pidtc.rarediseasesnetwork.org/

21. Martinez FJ, Flaherty K. Pulmonary Function Testing in Idiopathic Interstitial Pneumonias. Proc Am
Thorac Soc. 2006 Jun;3(4):315–21.

22. Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ. 2023
Feb 6;380:e070201.

23. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Ravà L, et al. B Cell Reconstitution after
Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol. 2016 Jun;27(6):1811–
22.

24. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following
rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte
homeostasis. Blood. 2005 Aug 1;106(3):795–802.

25. Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, et al. Misdiagnosis of primary immune
thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood
Advances. 2017 Nov 28;1(25):2414–20.

26. Newburger PE. Autoimmune and other acquired neutropenias. Hematology. 2016 Dec 2;2016(1):38–
42.

27. Bryant N, Watts R. Thrombocytopenic Syndromes Masquerading as Childhood Immune
Thrombocytopenic Purpura. Clin Pediatr (Phila). 2011 Mar 1;50(3):225–30.

28. Künzli M, Schreiner D, Pereboom TC, Swarnalekha N, Litzler LC, Lötscher J, et al. Long-lived T
follicular helper cells retain plasticity and help sustain humoral immunity. Sci Immunol. 2020 Mar
13;5(45):eaay5552.

29. Horowitz GL. Reference Intervals: Practical Aspects. EJIFCC. 2008 Oct 16;19(2):95–105.

30. Horowitz GL, editor. EP28A3C: Define and Verify Reference Intervals in Lab [Internet]. Vol. 28.
Clinical and Laboratory Standards Institute; 2010 [cited 2021 Aug 26]. Available from:
https://clsi.org/standards/products/method-evaluation/documents/ep28/

31. Blackburn JM, Shoko A. Protein function microarrays for customised systems-oriented proteome analysis. Methods Mol Biol. 2011;785:305–30.

32. Blackburn JM, Shoko A, Beeton-Kempen N. Miniaturized, microarray-based assays for chemical proteomic studies of protein function. Methods Mol Biol. 2012;800:133–62.

33. Liu X, Li N, Liu S, Wang J, Zhang N, Zheng X, et al. Normalization Methods for the Analysis of Unbalanced Transcriptome Data: A Review. Frontiers in Bioengineering and Biotechnology [Internet]. 2019 [cited 2024 Feb 24];7. Available from: https://www.frontiersin.org/articles/10.3389/fbioe.2019.00358

34. Ballman KV, Grill DE, Oberg AL, Therneau TM. Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics. 2004 Nov 1;20(16):2778–86.

35. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015 Apr 20;43(7):e47.

36. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007 Jan;8(1):118–27.

37. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012 Mar 15;28(6):882–3.

38. Horowitz GL, editor. CLSI EP28-A3C: Define and Verify Reference Intervals in Lab [Internet]. Vol. 28. Clinical and Laboratory Standards Institute; 2010 [cited 2021 Aug 26]. Available from: https://clsi.org/standards/products/method-evaluation/documents/ep28/

39. Gu Z. Complex heatmap visualization. iMeta. 2022;1(3):e43.

40. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016 Sep 15;32(18):2847–9.

41. Imdadullah M, Aslam M, Altaf S. mctest: An R Package for Detection of Collinearity among Regressors. The R Journal. 2016;8(2):495.

42. Chan AY, Torgerson TR. PIRD: Primary Immune Regulatory Disorders, A Growing Universe of Immune Dysregulation. Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):582–90.

43. Liang C, Spoerl S, Xiao Y, Habenicht KM, Haeusl SS, Sandner I, et al. Oligoclonal CD4+CXCR5+ T cells with a cytotoxic phenotype appear in tonsils and blood. Commun Biol. 2024 Jul 18;7(1):1–16.

44. Xu M, Jiang Y, Wang J, Liu D, Wang S, Yi H, et al. Distribution of distinct subsets of circulating T follicular helper cells in Kawasaki disease. BMC Pediatr. 2019 Jan 31;19(1):43.

45. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019 May;50(5):1132–48.

46. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and
Extracellular Proteins in Autoimmunity. Frontiers in Immunology [Internet]. 2021 [cited 2024 Jan
17];12. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.548469

47. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is
effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional
trial. Blood. 2016 Jan 7;127(1):17–28.

48. Murter B, Kane LP. Control of T lymphocyte fate decisions by PI3K signaling. F1000Res.
2020;9:F1000 Faculty Rev-1171.

49. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and
Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017 Apr 26;35:337–70.

50. Nagafuchi Y, Yanaoka H, Fujio K. Lessons From Transcriptome Analysis of Autoimmune Diseases.
Frontiers in Immunology [Internet]. 2022 [cited 2024 Jan 18];13. Available from:
https://www.frontiersin.org/articles/10.3389/fimmu.2022.857269

51. Miyamoto T, Fukunaga Y, Ogasawara A, Munakata A, Murai K. Autoantibody profiles in
intravenous immunoglobulin preparations: A possible cause of mistaken autoimmunity diagnosis.
Transfusion. 2024 Apr;64(4):597–605.

52. Bodansky A, Mettelman RC, Sabatino JJ, Vazquez SE, Chou J, Novak T, et al. Molecular mimicry in
multisystem inflammatory syndrome in children. Nature. 2024 Aug 15;632(8025):622–9.

53. Wei X, Niu X. T follicular helper cells in autoimmune diseases. Journal of Autoimmunity. 2023
Jan;134:102976.

54. Search Results [Internet]. [cited 2024 Nov 22]. Available from: https://www.biolegend.com/de-
at/search-results

55. Autoantibodies | Powerful Biomarkers for Precision Medicine [Internet]. Sengenics. [cited 2024 Nov
22]. Available from: https://sengenics.com/technology/autoantibodies-as-biomarkers/

56. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical
diversity. Blood. 2009 Jun 25;113(26):6511–21.

57. Kumar D, Prince C, Bennett CM, Briones M, Lucas L, Russell A, et al. T-follicular helper cell
expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome.
Blood. 2022 Jan 20;139(3):369–83.

58. Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, et al. Loss of Circulating CD4
T Cells with B Cell Helper Function during Chronic HIV Infection. PLOS Pathogens. 2014 Jan
30;10(1):e1003853.

59. Barbi J, Oghumu S, Lezama-Davila CM, Satoskar AR. IFN-gamma and STAT1 are required for
efficient induction of CXC chemokine receptor 3 (CXCR3) on CD4+ but not CD8+ T cells. Blood.
2007 Sep 15;110(6):2215–6.

60. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions.
Immunol Cell Biol. 2011 Feb;89(2):207–15.

61. Groom JR, Luster AD. CXCR3 in T cell function. Experimental Cell Research. 2011
Mar;317(5):620–31.

62. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically
expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017 Feb
1;542(7639):110–4.

63. Marks KE, Rao DA. T peripheral helper cells in autoimmune diseases. Immunol Rev. 2022
May;307(1):191–202.

64. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, et al. Pro-inflammatory
human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. Journal
of Experimental Medicine. 2014 Jan 13;211(1):89–104.

65. Koetzier SC, Van Langelaar J, Blok KM, Van Den Bosch TPP, Wierenga-Wolf AF, Melief MJ, et al.
Brain-homing CD4 [+] T cells display glucocorticoid-resistant features in MS. Neurol Neuroimmunol
Neuroinflamm. 2020 Nov;7(6):e894.

66. Ma CS, Phan TG. Here, there and everywhere: T follicular helper cells on the move. Immunology.
2017 Nov;152(3):382–7.

67. Nguyen QP, Deng TZ, Witherden DA, Goldrath AW. Origins of CD4+ circulating and tissue-resident
memory T-cells. Immunology. 2019;157(1):3–12.

68. Walters GD, Vinuesa CG. T Follicular Helper Cells in Transplantation. Transplantation. 2016
Aug;100(8):1650–5.

Figure legends
616
Figure 1. cTfh and cTfm analysis among patients and controls. a. Percentages of CD4[+]CXCR5[+]PD-1[+] cTfh cells
in patients (Pts, n=101) and controls (Ctrls, n=74). Dotted line at 12% represents the upper limit of normal, as
previously published. *p*-values were calculated by two-tailed Mann-Whitney test. **b.** Gating strategy for identifying
chemokine receptor skewing of cTfm cells. **c.** Percentages of CXCR3[+]CCR6[-], CXCR3[+]CCR6[+], CXCR3[-]CCR6[+],
CXCR3[-]CCR6[-] cTfm cells in patients (Pts, n=101) and controls (Ctrls, n=74). *p*-values were calculated by two-tailed
Mann-Whitney test adjusted for multiple comparisons. **d.** Flow diagram demonstrating the proportions of patients
(n=101) with normal (green) vs. abnormal (red) cTfh % and chemokine receptor skewing of cTfm cells **e.**
Multivariate logistic regression of cTfm skewing as a function of presence of monogenic disease, active disease
status, and active treatment status. **f.** Distribution of elevated cTfh and chemokine receptor skewing of cTfm cells
among individual patients (n=101).
627
628 **Figure 2. Autoantibody burden and pathway analysis among patients and controls. a.** Total number of high-
629 titer IgG autoantibodies in patients (black, n=56) and controls (white, n=20). **b.** Pathways enriched in high-titer IgG
630 autoantibodies found only in the patient cohort. **c.** Total number of high-titer IgA autoantibodies in patients (black,
631 n=56) and controls (white, n=20). **d.** Pathways enriched in high-titer IgA autoantibodies found only in the patient
632 cohort.
633
Figure 3. Associations between cTfh%, cTfm skewing, and autoantibody burden. a. Contingency tables using
Fisher's exact test to determine that neither elevated cTfh nor cTfm skewing correlates with autoantibody burden. **b.**
Contingency table of elevated composite measure, defined as elevated cTfh, cTfm subset skewing, and/or high
autoantibody burden in patients with and without PIRD. Sensitivity was defined as the proportion with an elevated
composite measure among those who had PIRD (40/56), and specificity was defined as the proportion with a normal

composite measure among those who did not have PIRD (17/20)**. c.** Proportion of normal (green) versus abnormal
(red) cTfh percentages, cTfm subsets, and autoantibody burdens in cohort of 56 patients with PIRD.

Table 1. Characteristics of study cohort and controls

Supplementary Figure 1. Percentages of cTfh cells and cTfm cells in patients receiving different types of
treatments. For each treatment, "+" and "–" indicates that the patient was either receiving or not receiving each
treatment, respectively, as described in the methods. **a.** IVIG (+ n=29, - n=72) **b.** Corticosteroids (+ n=23, - n=78) **c.**
Rituximab (+ n=13, - n=88) **d.** Mycophenolate (+ n=15, - n=86) **e.** Sirolimus (+ n=9, - n=92). Horizontal dotted line
at 12% on cTfh plots represents the upper limit of normal, as previously published. Horizontal dotted lines on cTfm
plots represent 97.5 and 2.5 percentile of controls. *p*-values were calculated by two-tailed Mann-Whitney test
adjusted for multiple comparisons.

Supplementary Figure 2. Percentages of CD4$^+$CXCR5$^-$PD1^{high} Tph cells in patients (Pts) and controls (Ctrls)
**p<0.01 by two-tailed Mann-Whitney test.

Supplementary Figure 3. **Association of high-titer autoantibody number with disease activity and treatment**
status. **a.** Number of high-titer IgG and IgA autoantibodies in patients with active (+) and inactive (-) disease. **b.**
Number of high-titer IgG and IgA autoantibodies in patients on treatment (+) and not on treatment (-) at time of
enrollment. Horizontal lines indicate median, error bars indicate the interquartile range. ns, *p*>0.05 by two-tailed
Mann-Whitney test. Y axis is log$_2$ scaled. UD = undetectable

Supplementary Figure 4. **Heatmap with unsupervised clustering based on the normalized net intensities of**
IgG autoantibodies in patients and controls. Patients who had received IVIG within the preceding four weeks
were excluded. Red: present, grey: inactive, white: not present (control).

Supplementary Figure 5. **Heatmap with unsupervised clustering based on the normalized net intensities of**
IgA autoantibodies in patients and controls. Red: present, grey: inactive, white: not present (control).

Supplementary Table 1: Genetic diagnoses of patients with monogenic disorders

Supplementary Data 1. IgG autoantibody net normalized intensities in patients and controls

Supplementary Data 2. IgA autoantibody net normalized intensities in patients and controls

Supplementary Data 3. High titer IgG autoantibodies with subcellular locations

Supplementary Data 4: High titer IgA autoantibodies with subcellular locations

Supplementary Data 5: Comparison of the top five enriched pathways for IgG targets in cohort including IVIg
recipients (n=56) as compared to cohort excluding IVIg recipients (n=39).

Autoimmunity

Peripheral Circulation

IgA

Autoantibodies

Memory B cell

IgG

B cell follicle

CD4+ T cell

B cell

TFH cell

CD4+CXCR5+PD1+

To circulation

CXCR5+CXCR3+CCR6+

CXCR5+CXCR3−CCR6+

Table I. Clinical characteristics of study cohort

	PIRD n=101	Controls n=74
Age in years (median, range)	14.35 (0.3-42)	10.5 (1.3-47.1)
Female (n, %)	47 (46.5)	41 (55.4)
Race (n, %)		
White	68 (67.3)	46 (62.1)
Black or African American	5 (4.9)	4 (5.4)
Asian	2 (1.9)	3 (4)
Middle Eastern	2 (1.9)	3 (4)
Other	8 (7.9)	7 (9.5)
Undisclosed	16 (15.8)	11 (14.8)
Ethnicity (n, %)		
Hispanic or Latino	11 (10.9)	11 (14.9)
Non-Hispanic	67 (66.3)	52 (70.2)
Undisclosed	23 (22.8)	11 (14.9)
Clinical features (n, %)		
Monogenic cause of autoimmunity	28 (27.7)	
Immune cytopenia	81 (80)	
Immune thrombocytopenia	24	
Autoimmune hemolytic anemia	22	
Evans Syndrome	35	
Interstitial lung disease	6 (5.9)	
Immune hepatitis	9 (8.9)	
Other autoimmune gastrointestinal disease: inflammatory bowel disease, autoimmune pancreatitis, celiac	10 (9.9)	
Autoimmune neurologic diseases: Guillain Barre, multiple sclerosis	4 (3.9)	
Autoimmune thyroiditis	5 (4.9)	
Active disease	59 (58.4)	
On treatment at enrollment	74 (73.2)	
Intravenous immune globulin	29	
Corticosteroid	23	
Rituximab	13	
Mycophenolate mofetil	15	
Sirolimus	9	

Figure 1

Figure 2

a.

High autoAb burden >15 IgG autoAb

No. participants

No. high-titer IgG autoantibodies

Controls Patients

b.

Pathways enriched in high-titer IgG autoantibodies unique to patients

Cell senescence — 23 antigens
Cell Cycle — 18 antigens
Insulin Signaling — 15 antigens
Mitophagy — 10 antigens
PI3K/AKT/mTOR — 24 antigens

Adjusted p value

c.

High autoAb burden >4 IgA autoAb

No. participants

No. high-titer IgA autoantibodies

Controls Patients

d.

Pathways enriched in high-titer IgA autoantibodies unique to patients

Glucagon Signaling — 16 antigens
Cell senescence — 17 antigens
Mitophagy — 9 antigens
Glycolysis/Gluconeogenesis — 8 antigens
Ferroptosis — 6 antigens

Adjusted p value

Figure 3

a.

	Elevated cTfh%	Normal cTfh%	Total
High Autoantibody Burden	6	15	21
Normal Autoantibody Burden	12	23	35
Total	18	38	56

	cTfm subset skewing	No cTfm subset skewing	Total
High Autoantibody Burden	10	11	21
Normal Autoantibody Burden	14	21	35
Total	24	32	56

b.

	PIRD	No PIRD	Total
Elevated Composite Measure	40	3	43
Normal Composite Measure	16	17	33
Total	56	20	76

c.